Management, Survival, and Costs of Pancreatic Cancer: Population-Based Observational Study in Catalonia

Laura Guarga, Noelia Paco, Paula Manchon-Walsh, Emili Vela, Joaquim Delgadillo, Caridad Pontes and Josep Maria Borràs ()
Additional contact information
Laura Guarga: Catalan Health Service (CatSalut), 08007 Barcelona, Spain
Noelia Paco: Catalan Health Service (CatSalut), 08007 Barcelona, Spain
Paula Manchon-Walsh: Catalan Cancer Plan, Department of Health, Hospitalet del Llobregat, 08908 Barcelona, Spain
Emili Vela: Catalan Health Service (CatSalut), 08007 Barcelona, Spain
Joaquim Delgadillo: Blood and Tissue Bank, 08005 Barcelona, Spain
Caridad Pontes: Catalan Health Service (CatSalut), 08007 Barcelona, Spain
Josep Maria Borràs: Catalan Cancer Plan, Department of Health, Hospitalet del Llobregat, 08908 Barcelona, Spain

IJERPH, 2023, vol. 20, issue 9, 1-15

Abstract: Aim: Few published studies comprehensively describe the characteristics of patients with pancreatic cancer and their treatment in clinical practice. This study aimed to describe the current clinical practice for treating pancreatic cancer in Catalonia, along with the associated survival and treatment costs. Methods: A retrospective observational cohort study in patients diagnosed with pancreatic cancer from 2014 to 2018, using data from the healthcare records of the Public Health System of Catalonia, was conducted. Treatment patterns and costs were described by age groups from 2014 to 2018, with survival reported until December 2021. Results: The proportion of patients receiving surgery with curative intent was low, especially in older patients (23% of patients <60 years and 9% of patients ≥80 years). The percentage of patients treated with drugs for unresectable disease also decreased with age (45% of patients <60 years and 8% of patients ≥80 years). Although age was associated with significant differences in survival after curative surgery, no differences attributable to age were observed in patients who received pharmacological treatment for unresectable disease. In patients under 60 years of age, the mean cost of the first year of treatment was EUR 17,730 (standard deviation [SD] 5754) in those receiving surgery and EUR 5398 (SD 9581) in those on pharmacological treatment for unresectable disease. In patients over 80, the mean costs were EUR 15,339 (SD 2634) and EUR 1845 (SD 3413), respectively. Conclusions: Half of the patients diagnosed with pancreatic cancer did not receive specific treatment. Surgery with curative intent was associated with longer survival, but only 18% of (mostly younger) patients received this treatment. Chemotherapy was also used less frequently in patients of advanced age, though survival in treated patients was comparable across all age groups, so careful oncogeriatric assessment is advisable to ensure the most appropriate indication for eligibility in older patients. In general, earlier diagnosis and more effective pharmacological treatments are necessary to treat frail patients with high comorbidity, a common profile in older patients.

Keywords: pancreatic cancer; real-world data; early diagnosis; overall survival; treatment cost; oncogeriatric (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/20/9/5673/pdf (application/pdf)
https://www.mdpi.com/1660-4601/20/9/5673/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:20:y:2023:i:9:p:5673-:d:1135056

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().